Spondyloarthritis

Secukinumab Associated With Reduced Synovitis in Psoriatic Arthritis

The 52-week double-blind, placebo-controlled ULTIMATE study included 166 adult biologic-naive patients with active psoriatic arthritis.

Study Supports Safety, Efficacy of Tofacitinib in the Treatment of Ankylosing Spondylitis

Researchers evaluated the safety and efficacy of tofacitinib for the treatment of patients with ankylosing spondylitis.

Guselkumab Provides Sustained Improvements Through 1 Year in Patients With Active Psoriatic Arthritis

Study authors reported on the 1-year safety and efficacy of guselkumab treatment in patients with active psoriatic arthritis.

Weight Loss Linked to Reduced Disease Activity in Patients With Psoriatic Arthritis and Obesity

Researchers assessed the effects of weight loss on disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity.

Undiagnosed Axial Spondyloarthritis Prevalent Among Patients With Inflammatory Bowel Disease

Study authors evaluated the prevalence of axial spondyloarthritis in patients with inflammatory bowel disease in secondary care.

Gut Microbiome Changes Different in Ankylosing Spondylitis and IBD, Associated With Disease Activity

Researchers assessed whether the gut microbiome in ankylosing spondylitis and inflammatory bowel disease was different, and whether it correlated with disease activity.

Ixekizumab Superior to Placebo in Self-Reported Functioning and Health in Patients With Axial Spondyloarthritis

Researchers evaluated the effect of ixekizumab on self-reported functioning and health in patients with active nonradiographic axial spondyloarthritis.

Impaired Spinal Mobility Independently Linked to Clinical Disease Activity in Axial Spondyloarthritis

Researchers explored the determinants of impaired spinal and hip mobility in patients with early axial spondyloarthritis.

Response to Secukinumab Shows Variations Across Psoriatic Arthritis Clusters

Researchers compared the effect of secukinumab on the quality of life of patients with very early and established psoriatic arthritis.

Infliximab Shows Favorable Initial Efficacy, But Drug Survival Diminishes in Psoriasis, PsA

Survival and discontinuation rates of infliximab when treating psoriasis in real world conditions were analyzed.